Maiva Pharma Private Limited, a leading US FDA-approved sterile injectables manufacturer, has officially inaugurated its brand-new manufacturing plant. Spanning a sprawling 22-acre campus in Shoolagiri, Tamil Nadu, the advanced facility significantly accelerates the company’s capacity to support global biotechnology and pharmaceutical innovators.
The newly unveiled first phase features highly sophisticated, dedicated production lines engineered for complex dosage forms, including vials, pre-filled syringes (PFS), cartridges, and lyophilized products. To ensure compliance with the highest international regulatory standards, Maiva Pharma has integrated cutting-edge, isolator-based filling technology. This specialized infrastructure provides unparalleled sterility assurance, superior process flexibility, and enhanced operational efficiency.
Complementing its high-volume manufacturing capabilities, the site hosts fully self-contained, world-class quality control and microbiology laboratories. These technical centers are fully equipped to support the end-to-end product lifecycle, ensuring seamless transfer, validation, and commercialization of critical therapies.
This strategic expansion reinforces Maiva Pharma’s commitment to addressing the growing global demand for high-quality sterile injectables while cementing Tamil Nadu’s position as a premier hub for high-tech pharmaceutical manufacturing.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
